Market Research Reports and Industry Reports

Synovial Sarcoma - Pipeline Review, H1 2016

  • DESCRIPTION
  • TABLE OF
    CONTENTS
  • RELATED
    REPORTS
  • SAMPLE REQUEST
  • PURCHASE BY
    SECTION

 Synovial Sarcoma - Pipeline Review, H1 2016
 
 Summary
 

 Global Markets Direct’s, ‘Synovial Sarcoma - Pipeline Review, H1 2016’, provides an overview of the Synovial Sarcoma pipeline landscape.
 
 The report provides comprehensive information on the therapeutics under development for Synovial Sarcoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Synovial Sarcoma and features dormant and discontinued projects.
 
 Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
 
 The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
 
 Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
 
 Scope
 
 - The report provides a snapshot of the global therapeutic landscape of Synovial Sarcoma
 - The report reviews pipeline therapeutics for Synovial Sarcoma by companies and universities/research institutes based on information derived from company and industry-specific sources
 - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
 - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
 - The report reviews key players involved Synovial Sarcoma therapeutics and enlists all their major and minor projects
 - The report assesses Synovial Sarcoma therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
 - The report summarizes all the dormant and discontinued pipeline projects
 - The report reviews latest news related to pipeline therapeutics for Synovial Sarcoma
 
 Reasons to buy
 
 - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
 - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
 - Identify and understand important and diverse types of therapeutics under development for Synovial Sarcoma
 - Identify potential new clients or partners in the target demographic
 - Develop strategic initiatives by understanding the focus areas of leading companies
 - Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
 - Devise corrective measures for pipeline projects by understanding Synovial Sarcoma pipeline depth and focus of Indication therapeutics
 - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
 - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
 

 Introduction 6
 Global Markets Direct Report Coverage 6
 Synovial Sarcoma Overview 7
 Therapeutics Development 8
 Pipeline Products for Synovial Sarcoma - Overview 8
 Pipeline Products for Synovial Sarcoma - Comparative Analysis 9
 Synovial Sarcoma - Therapeutics under Development by Companies 10
 Synovial Sarcoma - Therapeutics under Investigation by Universities/Institutes 11
 Synovial Sarcoma - Pipeline Products Glance 12
 Clinical Stage Products 12
 Early Stage Products 13
 Synovial Sarcoma - Products under Development by Companies 14
 Synovial Sarcoma - Products under Investigation by Universities/Institutes 15
 Synovial Sarcoma - Companies Involved in Therapeutics Development 16
 Adaptimmune Therapeutics Plc 16
 Advenchen Laboratories, LLC 17
 EpiZyme, Inc. 18
 Immune Design Corp. 19
 Karyopharm Therapeutics, Inc. 20
 Merck & Co., Inc. 21
 Novartis AG 22
 OncoTherapy Science, Inc. 23
 Takara Bio Inc. 24
 Synovial Sarcoma - Therapeutics Assessment 25
 Assessment by Monotherapy Products 25
 Assessment by Target 26
 Assessment by Mechanism of Action 28
 Assessment by Route of Administration 30
 Assessment by Molecule Type 32
 Drug Profiles 34
 AL-3818 - Drug Profile 34
 Product Description 34
 Mechanism of Action 34
 R&D Progress 34
 Cellular Immunotherapy to Target MAGE-A1, MAGE-A3 and NY-ESO-1 for Oncology - Drug Profile 36
 Product Description 36
 Mechanism of Action 36
 R&D Progress 36
 CMB-305 - Drug Profile 37
 Product Description 37
 Mechanism of Action 37
 R&D Progress 37
 everolimus - Drug Profile 39
 Product Description 39
 Mechanism of Action 39
 R&D Progress 39
 GSK-3377794 - Drug Profile 46
 Product Description 46
 Mechanism of Action 46
 R&D Progress 46
 OTSA-101 - Drug Profile 48
 Product Description 48
 Mechanism of Action 48
 R&D Progress 48
 pembrolizumab - Drug Profile 49
 Product Description 49
 Mechanism of Action 49
 R&D Progress 49
 selinexor - Drug Profile 59
 Product Description 59
 Mechanism of Action 59
 R&D Progress 59
 SSTC-104 - Drug Profile 65
 Product Description 65
 Mechanism of Action 65
 R&D Progress 65
 tazemetostat - Drug Profile 66
 Product Description 66
 Mechanism of Action 66
 R&D Progress 66
 TBI-1301 - Drug Profile 68
 Product Description 68
 Mechanism of Action 68
 R&D Progress 68
 Synovial Sarcoma - Recent Pipeline Updates 69
 Synovial Sarcoma - Discontinued Products 112
 Synovial Sarcoma - Product Development Milestones 113
 Featured News & Press Releases 113
 Feb 09, 2016: U.S. Food and Drug Administration Grants Breakthrough Therapy Designation for Adaptimmune’s Affinity Enhanced T-cell Therapy Targeting NY-ESO in Synovial Sarcoma 113
 Feb 02, 2016: Adaptimmune and GSK expand Strategic Immunotherapy Collaboration 113
 Dec 30, 2015: Epizyme Announces First Patient Dosed in Global Clinical Program Evaluating Tazemetostat in Genetically Defined Solid Tumors 114
 Nov 05, 2015: Adaptimmune Announces Data From Clinical Study of NY-ESO Affinity Enhanced T-Cell Therapy in Synovial Sarcoma at the 2015 Annual Meeting of the Society of Immunotherapy for Cancer 116
 Oct 30, 2015: Adaptimmune To Present new data from NY-ESO at the 2015 Annual Meeting of the Society of Immunotherapy for Cancer 118
 Sep 01, 2015: Adaptimmune Expands Trial of T-cell Therapy for Synovial Sarcoma and Achieves Clinical Milestones 118
 Aug 24, 2015: Epizyme Announces Acceptance of Investigational New Drug Application for Tazemetostat in Patients with INI1-Negative Tumors or Synovial Sarcoma 119
 May 30, 2015: Adaptimmune Announces Data from Clinical Studies of NY-ESO-1 Specific T-Cells in Multiple Cancers at the 2015 Annual American Society of Clinical Oncology (ASCO) Meeting 121
 May 21, 2015: Adaptimmune Announces Upcoming Data Presentation at the 2015 Annual American Society of Clinical Oncology (ASCO) Meeting 122
 May 13, 2015: Adaptimmune Announces Upcoming Data Presentation at the 2015 Annual American Society of Gene and Cell Therapy (ASGCT) Meeting 123
 Appendix 124
 Methodology 124
 Coverage 124
 Secondary Research 124
 Primary Research 124
 Expert Panel Validation 124
 Contact Us 124
 Disclaimer 125


List Of Tables


Number of Products under Development for Synovial Sarcoma, H2 2014 7
Number of Products under Development for Synovial Sarcoma - Comparative Analysis, H2 2014 8
Number of Products under Development by Companies, H2 2014 9
Number of Products under Investigation by Universities/Institutes, H2 2014 10
Comparative Analysis by Clinical Stage Development, H2 2014 11
Comparative Analysis by Early Stage Development, H2 2014 12
Comparative Analysis by Unknown Stage Development, H2 2014 13
Products under Development by Companies, H2 2014 14
Products under Investigation by Universities/Institutes, H2 2014 15
Synovial Sarcoma - Pipeline by Adaptimmune Limited, H2 2014 16
Synovial Sarcoma - Pipeline by Eisai Co., Ltd., H2 2014 17
Synovial Sarcoma - Pipeline by Karyopharm Therapeutics, Inc., H2 2014 18
Synovial Sarcoma - Pipeline by Merck & Co., Inc., H2 2014 19
Synovial Sarcoma - Pipeline by Novartis AG, H2 2014 20
Synovial Sarcoma - Pipeline by OncoTherapy Science, Inc., H2 2014 21
Assessment by Monotherapy Products, H2 2014 22
Number of Products by Stage and Target, H2 2014 24
Number of Products by Stage and Mechanism of Action, H2 2014 26
Number of Products by Stage and Route of Administration, H2 2014 28
Number of Products by Stage and Molecule Type, H2 2014 30
Synovial Sarcoma Therapeutics - Recent Pipeline Updates, H2 2014 51
Synovial Sarcoma - Discontinued Products, H2 2014 72


List Of Figures

 Number of Products under Development for Synovial Sarcoma, H1 2016 8
 Number of Products under Development for Synovial Sarcoma - Comparative Analysis, H1 2016 9
 Number of Products under Development by Companies, H1 2016 10
 Comparative Analysis by Clinical Stage Development, H1 2016 12
 Assessment by Monotherapy Products, H1 2016 25
 Number of Products by Top 10 Targets, H1 2016 26
 Number of Products by Stage and Top 10 Targets, H1 2016 26
 Number of Products by Top 10 Mechanism of Actions, H1 2016 28
 Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 28
 Number of Products by Routes of Administration, H1 2016 30
 Number of Products by Stage and Routes of Administration, H1 2016 30
 Number of Products by Molecule Types, H1 2016 32
 Number of Products by Stage and Molecule Types, H1 2016 32


Synovial Sarcoma Global Clinical Trials Review, H1, 2015

Synovial Sarcoma Global Clinical Trials Review, H1, 2015GlobalData s clinical trial report, Synovial Sarcoma Global Clinical Trials Review, H1, 2015 provides data on the Synovial Sarcoma clinical trial scenario. This report

USD 2500View Report

Synovial Sarcoma - Pipeline Review, H1 2016

 Synovial Sarcoma - Pipeline Review, H1 2016        Global Markets Direct’s, ‘Synovial Sarcoma - Pipeline Review, H1 2016’, provides an overview of the Synovial Sarcoma pipeline landscape.

USD 2000View Report

Ewings sarcoma - Epidemiology Forecast To 2023

DelveInsight Ewings sarcoma - Epidemiology Forecast To 2023 provides an overview of the epidemiology trends of Ewings sarcoma in seven major markets (US, France, Germany, Italy, Spain, UK and Japan).

USD 2750View Report

Osteosarcoma - Epidemiology Forecast To 2023

DelveInsight Osteosarcoma - Epidemiology Forecast To 2023 provides an overview of the epidemiology trends of Osteosarcoma in seven major markets (US, France, Germany, Italy, Spain, UK and Japan). It includes

USD 2750View Report

AIDS Related Kaposis Sarcoma - Epidemiology Forecast To 2023

DelveInsight AIDS Related Kaposis Sarcoma - Epidemiology Forecast To 2023 provides an overview of the epidemiology trends of AIDS Related Kaposis Sarcoma in seven major markets (US, France, Germany, Italy,

USD 2750View Report

Fill The Form For Sample Request
Name*
Email*
Mobile No.*
LandLine No.
If you want to purchase particular section from this report then kindly contact us at contact@aarkstore.com.

Delivery Details

PDF FORMAT REPORTS will be delivered by email within 12 to 24 hours after placing the order (Mon-Fri IST)

CHOOSE FORMAT

Discount on PDF and Enterprise Wide Licence reports
  • PDF $ 2000    $ 2000
  • Site Licence $ 4000    $ 4000
  • Enterprise Wide Licence $ 6000    $ 6000
$ 2000

Reports Details

Published Date : Mar 2016
No. of Pages :125
Country :Global
Category :Healthcare
Publisher :Global Markets Direct
Report Delivery By :Email
Report Delivery Time :12 to 24 hours after placing the order.

Customized Research

If you do not find this specific report suitable to your exact needs then you can also opt for customized research report that will befit all your expectation. To specify your requirements CLICK HERE

 

We Accept

payment